Table 1.
Primers used for amplicon generation.
Table 2.
Demographic, clinical and virological characteristics of the included patients (n = 29).
Figure 1.
Drug resistant mutations (DRMs) detected by Sanger sequencing (SS) and ultra-deep sequencing (UDS).
Mean of DRMs per patients were obtained. Two-tailed p values and 95% confidence intervals were calculated from the paired Student t-test (ns: not statistically significant, p>0.05). ALL_SS and ALL_UDS: all DRMs detected by SS and UDS respectively PI_SS and PI_UDS: Protease inhibitor (PI)-DRMs detected by SS and UDS respectively NRTI_SS and NRTI_UDS: Nucleoside Reverse Transcriptase Inhibitor (NRTI)-DRMs detected by SS and UDS respectively. NNRTI_SS and NNRTI_UDS: Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)-DRMs detected by SS and UDS respectively.
Table 3.
List of drug resistance mutations (DRM) detected at baseline (BL) and virological failure (VF) by Sanger sequencing (SS) and UDS for patients failing a PI-based regimen (n = 15).
Table 4.
List of drug resistance mutations (DRM) detected at baseline (BL) and virological failure (VF) by Sanger sequencing (SS) and UDS for patients failing a NNRTI-based regimen (n = 6) or NRTI-based regimen (n = 8).